Role of Interleukin-17 cytokine family in human T-cell lymphotropic virus type 1 (HTLV-1) infection and associated diseases

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Cytokine Pub Date : 2024-07-31 DOI:10.1016/j.cyto.2024.156710

Mohammadreza Shafiei , Saleh Ghadimi , Pegah Baharlou , Faezeh Moghimi , Arash Letafati , Sayed-Hamidreza Mozhgani

{"title":"Role of Interleukin-17 cytokine family in human T-cell lymphotropic virus type 1 (HTLV-1) infection and associated diseases","authors":"Mohammadreza Shafiei , Saleh Ghadimi , Pegah Baharlou , Faezeh Moghimi , Arash Letafati , Sayed-Hamidreza Mozhgani","doi":"10.1016/j.cyto.2024.156710","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Human T-lymphotropic virus (HTLV-1) is a neglected virus with worldwide distribution of over 10 million people and is the cause of two main associated diseases Adult T cell Leukemia-Lymphoma (ATLL), and HTLV-1-associated Myelopathy/Tropical Spastic paraparesis (HAM/TSP). The IL-17 cytokine family plays a crucial role in the host immunity against HTLV-1 and the development of associated disease. A systematic review was conducted to analyze all research reporting on the levels or expression of the IL-17 HTLV-1 infection and associated diseases.</p></div><div><h3>Methods</h3><p>The literature search was conducted in electronic databases including PubMed/Medline and Web of Sciences until January 31st, 2024, followed by the PRISMA guidelines.</p></div><div><h3>Results</h3><p>Our search revealed 20 eligible articles to be included in our study. The total number of cases studied was 1420, of which 386 were carriers without any symptoms, and were 176 ATLL and 237 HAM/TSP. The IL-17 cytokine family production or mRNA expression was higher in HAM/TSP patients but showed a trend toward reduction in the case of ATLL.</p></div><div><h3>Conclusions</h3><p>Our results showed that while The IL-17 cytokine family plays a significant role in the immunopathogenesis of disease and clinical status of patients with inflammatory disorders such as HAM/TSP, IL-17 production is diminished and the RORC/IL-17 signaling pathway is downregulated during ATLL. Our data suggest that boosting the RORC/IL-17 signaling pathway in ATLL and using anti-IL-17 agents in HAM/TSP and other HTLV-related inflammatory conditions might benefit patients and improve their outcomes.</p></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"182 ","pages":"Article 156710"},"PeriodicalIF":3.7000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624002138","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Human T-lymphotropic virus (HTLV-1) is a neglected virus with worldwide distribution of over 10 million people and is the cause of two main associated diseases Adult T cell Leukemia-Lymphoma (ATLL), and HTLV-1-associated Myelopathy/Tropical Spastic paraparesis (HAM/TSP). The IL-17 cytokine family plays a crucial role in the host immunity against HTLV-1 and the development of associated disease. A systematic review was conducted to analyze all research reporting on the levels or expression of the IL-17 HTLV-1 infection and associated diseases.

Methods

The literature search was conducted in electronic databases including PubMed/Medline and Web of Sciences until January 31st, 2024, followed by the PRISMA guidelines.

Results

Our search revealed 20 eligible articles to be included in our study. The total number of cases studied was 1420, of which 386 were carriers without any symptoms, and were 176 ATLL and 237 HAM/TSP. The IL-17 cytokine family production or mRNA expression was higher in HAM/TSP patients but showed a trend toward reduction in the case of ATLL.

Conclusions

Our results showed that while The IL-17 cytokine family plays a significant role in the immunopathogenesis of disease and clinical status of patients with inflammatory disorders such as HAM/TSP, IL-17 production is diminished and the RORC/IL-17 signaling pathway is downregulated during ATLL. Our data suggest that boosting the RORC/IL-17 signaling pathway in ATLL and using anti-IL-17 agents in HAM/TSP and other HTLV-related inflammatory conditions might benefit patients and improve their outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

白细胞介素-17 细胞因子家族在人类 T 细胞淋巴病毒 1 型（HTLV-1）感染及相关疾病中的作用。

背景：人类 T 淋巴细胞病毒（HTLV-1）是一种被忽视的病毒，在全球的分布超过 1 千万人，是两种主要相关疾病成人 T 细胞白血病-淋巴瘤（ATLL）和 HTLV-1 相关骨髓病/热带痉挛性截瘫（HAM/TSP）的病因。IL-17 细胞因子家族在宿主对 HTLV-1 的免疫和相关疾病的发展中起着至关重要的作用。我们进行了一项系统性综述，分析了所有关于IL-17 HTLV-1感染和相关疾病的水平或表达的研究报告：按照PRISMA指南，在PubMed/Medline和Web of Sciences等电子数据库中进行文献检索，直至2024年1月31日：搜索结果显示，有 20 篇符合条件的文章被纳入研究。研究病例总数为 1420 例，其中 386 例为无任何症状的携带者，176 例为 ATLL，237 例为 HAM/TSP。HAM/TSP患者的IL-17细胞因子家族产生量或mRNA表达量较高，但ALL患者的IL-17细胞因子家族产生量或mRNA表达量呈下降趋势：我们的研究结果表明，虽然 IL-17 细胞因子家族在 HAM/TSP 等炎症性疾病患者的免疫发病机制和临床状态中发挥着重要作用，但在 ATLL 期间，IL-17 的产生减少，RORC/IL-17 信号通路下调。我们的数据表明，在 ATLL 中增强 RORC/IL-17 信号通路以及在 HAM/TSP 和其他 HTLV 相关炎症中使用抗 IL-17 药物可能会使患者受益，并改善他们的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.